[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:plasma-cell-leukemia":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":70,"states":71},"Plasma Cell Leukemia",10,[7,15,22,28,34,40,46,52,58,64],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05405387","Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant",[11],"Phase 2","RECRUITING","2026-08-26T02:17:32.059863Z","2026-07-05T05:32:16.799414Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06066359","Ph I\u002FII Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR\u002FIL-15 for R\u002FR Myeloma",[19],"Phase 1\u002FPhase 2","2026-08-26T02:17:58.890423Z","2026-06-18T04:29:21.268683Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT05208307","Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma",[11],"2026-08-26T02:17:40.683658Z","2026-05-05T02:43:29.069274Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06517017","Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma",[11],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:27.658825Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[11],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.206546Z",{"nct_id":41,"title":42,"phases":43,"status":12,"updated_at":44,"content_modified":45},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[11],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":47,"title":48,"phases":49,"status":12,"updated_at":50,"content_modified":51},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[19],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.847376Z",{"nct_id":53,"title":54,"phases":55,"status":12,"updated_at":56,"content_modified":57},"NCT03127761","Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma",[],"2026-08-26T02:16:13.426928Z","2026-05-13T02:55:06.108057Z",{"nct_id":59,"title":60,"phases":61,"status":12,"updated_at":62,"content_modified":63},"NCT05556928","Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry",[],"2026-08-26T02:15:00.557154Z","2026-05-13T02:55:06.362539Z",{"nct_id":65,"title":66,"phases":67,"status":12,"updated_at":68,"content_modified":69},"NCT03717844","Registry for Adults With Plasma Cell Disorders (PCD's)",[],"2026-08-26T02:18:13.438956Z","2026-05-13T02:55:06.175931Z",[],[72],{"state":73,"count":74,"slug":75},"Minnesota",3,"minnesota"]